scispace - formally typeset
Open AccessJournal ArticleDOI

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.

TLDR
The phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein in healthy adults found it induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100- μg dose in a phase 3 vaccine trial.
Abstract
Background Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased inciden...

read more

Citations
More filters
Journal Article

Coronavirus disease (COVID-19) pandemic.

TL;DR: In this article, the authors proposed a method to solve the problem of "no abstracts" and "no-no-expansions" in the context of artificial intelligence.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Journal ArticleDOI

Lipid nanoparticles for mRNA delivery.

TL;DR: A review of lipid nanoparticles for mRNA delivery can be found in this paper, where the authors discuss the design of nanoparticles and examine physiological barriers and possible administration routes for lipid nanoparticle-mRNA systems.
References
More filters
Journal ArticleDOI

A new coronavirus associated with human respiratory disease in China.

TL;DR: Phylogenetic and metagenomic analyses of the complete viral genome of a new coronavirus from the family Coronaviridae reveal that the virus is closely related to a group of SARS-like coronaviruses found in bats in China.
Journal ArticleDOI

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.

TL;DR: A cohort of asymptomatic patients infected with SARS-CoV-2 had significantly lower levels of virus-specific IgG antibodies compared to a cohort of age- and sex-matched symptomatic infected patients.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -